Endonovo Therapeutics (ENDV) Other Non Operating Income (2016 - 2023)
Endonovo Therapeutics has reported Other Non Operating Income over the past 9 years, most recently at -$15328.0 for Q2 2023.
- Quarterly results put Other Non Operating Income at -$15328.0 for Q2 2023, down 114.63% from a year ago — trailing twelve months through Sep 2023 was -$13.8 million (down 1138.26% YoY), and the annual figure for FY2022 was -$14.0 million, down 63390.98%.
- Other Non Operating Income for Q2 2023 was -$15328.0 at Endonovo Therapeutics, down from $52460.0 in the prior quarter.
- Over the last five years, Other Non Operating Income for ENDV hit a ceiling of $6.5 million in Q1 2020 and a floor of -$13.8 million in Q4 2022.
- Median Other Non Operating Income over the past 5 years was -$7458.0 (2019), compared with a mean of -$992182.1.
- Biggest five-year swings in Other Non Operating Income: soared 75742.73% in 2020 and later plummeted 216681.72% in 2022.
- Endonovo Therapeutics' Other Non Operating Income stood at -$7.6 million in 2019, then skyrocketed by 175.03% to $5.7 million in 2020, then tumbled by 100.11% to -$6374.0 in 2021, then plummeted by 216681.72% to -$13.8 million in 2022, then soared by 99.89% to -$15328.0 in 2023.
- The last three reported values for Other Non Operating Income were -$15328.0 (Q2 2023), $52460.0 (Q1 2023), and -$13.8 million (Q4 2022) per Business Quant data.